Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exceptional Access Program for use of VENCLEXTA®(venetoclax) monotherapy in treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

Next Previous
Trial Profile

Exceptional Access Program for use of VENCLEXTA®(venetoclax) monotherapy in treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 28 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Sponsors AbbVie

Most Recent Events

  • 28 May 2019 New trial record
  • 23 May 2019 According to an AbbVie Media release, the company signed an agreement with pan-Canadian Pharmaceutical Alliance(pCPA) and announced that Ontario is the first province to reimburse VENCLEXTA(venetoclax) monotherapy under its Drugs and Devices Division's (DDD) Exceptional Access Program for patients with chronic lymphocytic leukemia(CLL).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top